<DOC>
	<DOCNO>NCT02676895</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity two different dos GVGH S. sonnei vaccine healthy adult represent first step towards test GMMA vaccine vaccine target population child develop country shigellosis endemic .</brief_summary>
	<brief_title>A Study Safety Immune Response 2 Doses New Shigella Vaccine Kenyan Adults</brief_title>
	<detailed_description />
	<mesh_term>Dysentery , Bacillary</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Individuals ≥18 year ≤45 year age day inform consent resident study area planning leave study period . 2 . Individuals , nature study explain , voluntarily give write consent accord local regulatory requirement , prior study entry . 3 . Individuals comply study procedure include followup . 4 . Individuals good health determine outcome medical history , physical examination , hematology , renal function , liver function test , urine dipstick/urinalysis clinical judgment investigator . 5 . Males Or Females childbearing potential use effective birth control method intend use duration study Or Females without childbearing potential ( i.e . irrespective birth control method ) Prior receipt second study vaccination , subject must evaluate confirm eligible subsequent vaccination . If subject meet original inclusion criterion list , receive additional vaccination . 1 . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study . 2 . Individuals progressive severe neurological disorder , seizure disorder previous GuillainBarré syndrome . 3 . Individuals , judgment investigator , may able comply require study procedure . 4 . Individuals history illness , opinion investigator , might interfere result study pose additional risk subject due participation study . 5 . Individuals history reactive arthritis . 6 . Individuals know HIV hepatitis B virus infection HIV related disease , history autoimmune disorder know suspected impairment /alteration immune system . Individuals systemic administration corticosteroid ( PO/IV/IM ) 14 consecutive day within 90 day prior screen . 7 . Individuals know bleed diathesis , condition may associate prolonged bleeding time . 8 . Individuals neutrophil count lower 1.8 x 10^9/L ( applicable initial 18 subject ) low 1.0 x 10^9/L ( applicable additional subject approve DSMB ) screen 9 . Individuals serious chronic progressive disease accord judgment investigator ( e.g. , neoplasm , insulin dependent diabetes , Type 2 diabetes mellitus , hypertension , cardiac , renal hepatic disease tuberculosis ) . 10 . Individuals malignancy lymphoproliferative disorder . 11 . Individuals history allergy vaccine component allergy deem investigator increase risk adverse event participate trial . 12 . Individuals participate clinical trial another investigational product within 28 day prior screen study visit intent participate another clinical study time conduct study . 13 . Individuals receive vaccine contain meningococcal A , C , W , Y tetanus , diphtheria pertussis antigen within 12 month screen , vaccine within 4 week prior screen study plan receive vaccine within entire study duration . 14 . Individuals receive blood , blood product , and/or plasma derivative include parenteral immunoglobulin preparation 12 week prior first dose study vaccine . 15 . Individuals study personnel immediate family member ( parent , child , spouse brothers/sisters ) personnel conduct study . 16 . Individuals body temperature &gt; 38.0°C within 3 day intend study vaccination reason delay vaccination 17 . Individuals Body Mass Index ( BMI ) &gt; 30 kg/m^2 18 . Individuals history substance alcohol abuse within past 2 year . 19 . Women pregnant breastfeeding , childbearing age use ( two month precede 1st vaccination ) willing use acceptable contraceptive measure , duration study . If subject woman childbearing potential , must negative pregnancy test screen visit prior enrollment ( visit 1 ) . For purpose study acceptable method contraception oral , injected implantable contraceptive . 20 . Individuals previously laboratory confirm case disease cause S. sonnei . 21 . Any condition , opinion investigator , may pose increase unreasonable safety risk subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>